SIK1 and pulmonary fibrosis: In addition, ARN-3236 (a SIK2-selective inhibitor) and dasatinib (shown to be a pan-SIK inhibitor) both decrease lung inflammation and fibrosis in a bleomycin-induced pulmonary fibrosis model, suggesting that multiple SIK isoforms may regulate inflammation in vivo (226, 227).